PURCHASE, N.Y., Jan. 28 /PRNewswire-FirstCall/ – Nutrition 21, Inc. (Nasdaq:
NXXI), a developer and marketer of nutritional supplements that help consumers manage
blood sugar levels, improve cardiovascular health, enhance memory and address chronic
joint pain, will report financial results - prior to the opening of the market -
on Thursday, February 5, 2009 for the second quarter of fiscal year 2009, ended
December 31, 2008. The Company has scheduled a conference call to review the results
later that morning, Thursday, February 5, 2009 at 10:00AM ET.
Participants can dial (866) 562-9910 or (706) 679-5064 to access the conference
call, or can listen via a live Internet web cast, which can be found at
http://www.nutrition21.com. A replay of the call will be available by visiting
http://www.nutrition21.com for 30 days
or by calling (800) 642-1687 or (706) 645-9291, access code 83095496, through February
8, 2009.
About Nutrition 21
Nutrition 21, Inc., headquartered in Purchase, NY, is a nutritional bioscience company
and the maker of chromium picolinate-based and omega-3 fish oil-based supplements
with health benefits substantiated by clinical research. Nutrition 21 holds more
than 30 patents for nutrition products and uses. Nutrition 21's portfolio of health
and wellness brands include: Chromax®, Iceland Health Advanced Memory Formula™,
Diabetes Essentials®, Iceland Health® Maximum Strength Omega-3 and Iceland Health®
Joint Relief. The company also manufactures private label supplements and ingredients
for third parties. Nutrition 21 products are sold nationally through more than 29,000
major food, drug and super center stores as well as internationally. For more information
please visit http://www.nutrition21.com.
# # #
Contacts
Nutrition 21, Inc.
Alan Kirschbaum
914-701-4500
Lytham Partners, LLC
Joe Diaz, Robert Blum, Joe Dorame
(602) 889-9700
CONTACT: Alan Kirschbaum of Nutrition 21, Inc., +1-914-701-4500; or Joe Diaz or Robert Blum or Joe Dorame, all of Lytham Partners, LLC, +1-602-889-9700, for Nutrition 21, Inc. |
 |
